HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM ARANESP®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department.

• For Medical Pharmacy please fax requests to: 801-213-1547

• For Retail Pharmacy please fax requests to: 385-425-4052

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested:
Aranesp[®] (darbepoetin alfa)

Dosing/Frequency:_

If the request is for reauthorization, proceed to reauthorization section					
	Questions	Yes	No	Comments/Notes	
1.	Is the requesting provider a hematologist, oncologist,				
	nephrologist, or in consultation with one?				
2.	Does documentation show that the member's hemoglobin is <10			Please provide documentation	
	g/dL and/or that the hematocrit is <30%?				
3.	Does the member have one of the following indications:			Please provide documentation	
	 Anemia of chronic renal failure, 				
	 Anemia due to myelosuppressive chemotherapy with a 				
	minimum of 8 additional weeks of planned chemotherapy,				
	 Myelodysplasia or myelodysplastic syndrome? 				
4.	Does the member have one of the following indications:				
	 Request will be used as a substitute for red blood cell 				
	transfusion in patients who require immediate correction of				
	anemia,				
	 Uncontrolled hypertension, 				
	• Pure Red Cell Aplasia (PRCA) that begins after treatment with				
	erythropoietin drugs?				
REAUTHORIZATION					
1.	Is the request for reauthorization of therapy?				

2. Has the member responded to treatment, demonstrated by an			Please provide documentation			
improvement in the hematocrit and hemoglobin levels or a						
significant decrease in transfusion requirements?						
- · ·			Diagon provide de comentation			
3. Is current hemoglobin < 11g/dL OR > 10 to <12 g/dL?			Please provide documentation			
What medications and/or treatment modalities have been tried in the past for this condition? Please document						
name of treatment, reason for failure, treatment dates, etc.						
Additional information:						
Physician's Signature:						

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy PHARM-HU-008 Origination Date: 01/01/2022 Reviewed/Revised Date: 01/17/2024 Next Review Date: 01/17/2025 Current Effective Date: 02/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.